Merck's Keytruda slashes death risk by 31% in esophageal cancer victory

Merck's Keytruda slashes death risk by 31% in esophageal cancer victory

Source: 
Fierce Pharma
snippet: 

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one.